PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine

•PARP inhibitors are extremely effective treatment for patients with BRCA mutated ovarian cancer.•PARP inhibitors may cause clinical and financial toxicity without clinical benefit for patients with HRP ovarian cancer.•A “PARPi for all” strategy ignores critical lessons learned from the success of precision medicine.